White Paper
Psychedelics and Entactogens: Challenges Associated with Schedule I Therapeutic Development
![Psychedelics and Entactogens: Challenges Associated with Schedule I Therapeutic Development](/var/wrbm_gb_food_pharma/storage/images/_aliases/wrbm_product_file/publications/pharmaceutical-science/outsourcing-pharma.com/resources/regulatory-affairs/psychedelics-and-entactogens-challenges-associated-with-schedule-i-therapeutic-development/13335004-1-eng-GB/Psychedelics-and-Entactogens-Challenges-Associated-with-Schedule-I-Therapeutic-Development.png)
Under the Controlled Substances Act (CSA) in the United States, drugs that have the potential to be abused are scheduled into one of five Classes or Schedules (CI-V) as controlled substances. The scheduling method makes a distinction for drugs that have abuse potential and are not approved for medical use (i.e., Schedule I) versus drugs that are approved for medical use.